2nd Annual Companion Diagnostics & Biomarkers 2019


The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.

Over 100+ delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will be joining the Companion Diagnostics & Biomarkers 2019

Companion diagnostics market is growing due to continuous advancement in medical technology both for the diagnosis and the treatment of patients. Rise in the prevalence of diseases like cancer & HIV is fueling to the growth of companion diagnostics as it assist in determining the patient specific dose and drugs.

Over 20+ presentations and case studies focused on the key issues in Companion Diagnostics & Biomarkers. Join us at the Companion Diagnostics & Biomarkers 2019 in Porto

The 2nd Annual Companion Diagnostics & Biomarkers 2019 will provide valued information about new IVD regulations, Dx reimbursement strategy, market access strategy to ensure successful commercialization with pharma & biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

We sincerely hope you are able to join us for this year’s meeting and be part of a new paradigm of precision medicine at the 2nd Annual Companion Diagnostics & Biomarkers 2019!


  • Learn the recent advances and future perspectives in Companion Diagnostics & Biomarkers
  • Understand the key aspects & challenges of Clinical Biomarker development & qualification Solutions for clinical development of precision therapies
  • Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology
  • Latest US and EU CDx regulation and guidance
  • Regulatory landscapes for biomarkers and diagnostic tests
  • Main barriers to progression of precision medicine in drug development
  • The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
  • Options for biomarker based patient stratification in NON-ONCOLOGY clinical development
  • Key trends in targeted and immuno-oncology companion diagnostics
  • Understand how better pharma/payer communications will be essential as more biological drugs with CDx hit the market.
  • Strategic Partnerships for CDx – Challenges and Opportunities


The BioTech Pharma Summit (EPM Group) are exclusive events designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed mem- bers of academic and government institutions.
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Clinical Development
  • Regulatory Affairs
  • Molecular Diagnostics
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Immunology
  • Genomics
  • Insurers
  • Patient Advocates
  • Payers
  • Market Access
  • Medical Sciences
  • Commercialisation
  • Oncology
  • Non-oncology
  • Rare Diseases
  • Drug Development
  • Research

Get your Early Bird Ticket for the 2nd Annual Companion Diagnostics & Biomarkers 2019!

USE THE COUPON CODE: BKRI92 and get 500€ OFF till 31st of August 2018

*For Sponsorship/Exhibition enquires, please use the contact form below.

Head, Global Value, Access, & Pricing, Incyte, USA
Professor of Translational Science, UCD School of Medicine, University College Dublin, IE
Key Account Partner at Horizon Discovery, UK
Senior Medical Oncologist & Professor of Medicine at Institut Curie & UVSQ, FR
Senior Lecturer at Institute of Translational Medicine, University of Liverpool, UK
Director Healthcare Systems at Novartis, CH
Vice President MHS global IVD at TÜV SÜD, JP
Managing Director at Martina Kaufmann Strategic Consulting, DE
Vice President Translational Medicine at Pierre Fabre, FR
Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London, UK
Franchise Leader for Oncology Companion Diagnostics at AstraZeneca, UK
Managing Director at Unilabs Denmark
Director Business Development at Thermo Fisher Scientific, DE
Director, Head of Clinical Trials Biosample Mgmt. at Merck KGaA, DE
Chief Business Officer at HistogeneX, US
Vice President, Discovery Research at hVIVO
Partner, Personalized Medicine at Health Advances
Regular Package
Buy Ticket

Full access to Presentations

Full access to Networking sessions

Business Lunches

Gala Dinner

Premium Package
Buy Ticket

Full Access to Regular Package

Airport Pick-Up/Drop-Off

One-on-One Partnering Program

Hotel Accommodation